Chartwell Investment Partners LLC Boosts Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Chartwell Investment Partners LLC raised its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 63.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 19,172 shares of the company’s stock after acquiring an additional 7,447 shares during the period. Chartwell Investment Partners LLC’s holdings in Vera Therapeutics were worth $847,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC purchased a new stake in shares of Vera Therapeutics during the 1st quarter worth about $227,027,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Vera Therapeutics during the 1st quarter worth about $103,189,000. Samlyn Capital LLC boosted its stake in shares of Vera Therapeutics by 90.8% during the 2nd quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock worth $44,571,000 after acquiring an additional 586,410 shares in the last quarter. First Light Asset Management LLC boosted its stake in shares of Vera Therapeutics by 130.6% during the 2nd quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company’s stock worth $36,387,000 after acquiring an additional 569,590 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Vera Therapeutics by 31.5% during the 1st quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock worth $92,653,000 after acquiring an additional 515,106 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Stock Down 0.3 %

VERA stock opened at $48.54 on Wednesday. The company has a market cap of $2.66 billion, a price-to-earnings ratio of -18.60 and a beta of 1.03. The company has a current ratio of 21.43, a quick ratio of 21.43 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a 12 month low of $11.69 and a 12 month high of $50.78. The firm has a 50-day moving average of $41.95 and a two-hundred day moving average of $39.29.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). As a group, analysts forecast that Vera Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on VERA shares. Scotiabank assumed coverage on shares of Vera Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 target price on the stock. JPMorgan Chase & Co. upped their price target on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Wedbush upped their price target on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 price target on shares of Vera Therapeutics in a research report on Tuesday, October 1st. Finally, Guggenheim upped their price target on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. One analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $57.88.

Insider Transactions at Vera Therapeutics

In other news, Director Beth C. Seidenberg sold 1,177 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total transaction of $49,445.77. Following the completion of the sale, the director now owns 160,376 shares in the company, valued at $6,737,395.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Beth C. Seidenberg sold 1,177 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total transaction of $49,445.77. Following the completion of the sale, the director now owns 160,376 shares in the company, valued at $6,737,395.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marshall Fordyce sold 15,625 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $37.50, for a total transaction of $585,937.50. Following the sale, the chief executive officer now owns 307,972 shares of the company’s stock, valued at $11,548,950. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 104,398 shares of company stock worth $4,376,163 in the last 90 days. Insiders own 21.70% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.